Kymera Therapeutics (KYMR) Misses Q4 EPS by 11c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.88), $0.11 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $14.71 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bank First National Corp. (BFC) appoints three new directors to board
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth